Sermorelin
GRF 1-29, Geref
The GHRH fragment that was FDA-approved for a decade, then quietly withdrawn for commercial reasons rather than safety ones. That distinction still shapes its legal status.
Human trials
Approved as Geref in 1997 and discontinued by the manufacturer in 2008 for manufacturing and commercial reasons. The FDA later determined it was not withdrawn for safety or effectiveness, which is why compounding pharmacies can still legally prepare it.
What it is
Sermorelin is the first 29 amino acids of growth hormone releasing hormone, which turns out to be the whole biologically active part. It binds the GHRH receptor on the pituitary and asks it to release your own growth hormone.
Its half-life is about eleven minutes. That sounds like a flaw and is arguably the feature: the pulse it produces is short and sharp, which is what endogenous GH release actually looks like.
The regulatory history is the interesting part
Sermorelin was FDA-approved as Geref in 1997, mainly for growth hormone deficiency in children. EMD Serono discontinued it in 2008. The reasons were manufacturing difficulty and commercial viability, not safety.
That distinction has consequences. In 2013 the FDA formally determined Geref had not been withdrawn for safety or effectiveness reasons, and that finding is why compounding pharmacies can still legally prepare sermorelin while they cannot touch BPC-157 or ipamorelin.
So sermorelin occupies an unusual position: a drug with real approval history and a legal compounding pathway, sitting in a category otherwise dominated by grey-market research chemicals. If you want a GH secretagogue with the least regulatory weirdness attached, this is it.
What the evidence supports, and what it does not
The approval evidence is about paediatric growth hormone deficiency. It works there.
Almost nobody buying sermorelin today is a child with growth failure. The adult use, for body composition, recovery and sleep, has no comparable trial base. Sermorelin reliably raises GH in adults; whether raising GH this way produces the outcomes people want has not been demonstrated.
That is the same gap that runs through this entire class. Sermorelin is simply more honest about it, because it has an approved indication you can point at and see that it is not the one you are using it for.
Practical notes
- The short half-life means timing matters. Take it fasted, at night. Food near the dose raises insulin, and insulin blunts GH release.
- Frequently paired with ipamorelin, on the same logic as the CJC-1295 pairing: a GHRH analogue plus a ghrelin receptor agonist hit two different levers on the same pulse.
- Do not run it alongside tesamorelin or CJC-1295. All three are GHRH receptor agonists. You would be pushing the same receptor twice.
- Track IGF-1 if you are doing this seriously. It is the only cheap way to know whether anything is happening.
Side effects and warning signs
Commonly reported
- Injection-site redness, itching and swelling, the most common complaint by far
- Flushing or a head rush within minutes of injecting
- Vivid dreams and altered sleep architecture
- Mild fluid retention and joint aches at sustained use
Stop and get medical help
- Progressive numbness or weakness in the hands
- Rising fasting glucose, since GH antagonises insulin
- Any active malignancy
Sources
From the community
Discussion for this compound concentrates in r/Peptidesource and r/PeptideForum.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.